A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
about
A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
A robust two-stage design iden ...... or phase I/II clinical trials.
@en
A robust two-stage design iden ...... or phase I/II clinical trials.
@nl
type
label
A robust two-stage design iden ...... or phase I/II clinical trials.
@en
A robust two-stage design iden ...... or phase I/II clinical trials.
@nl
prefLabel
A robust two-stage design iden ...... or phase I/II clinical trials.
@en
A robust two-stage design iden ...... or phase I/II clinical trials.
@nl
P2860
P356
P1476
A robust two-stage design iden ...... or phase I/II clinical trials.
@en
P2093
P2860
P356
10.1002/SIM.7082
P407
P577
2016-08-18T00:00:00Z